B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T. Hutson, M. Michaelson, V. Gorbunova, M. Gore, I. Rusakov, S. Négrier, Y. Ou, D. Castellano, Ho Lim, H. Uemura, J. Tarazi, D. Cella, Connie Chen, B. Rosbrook, S. Kim, R. Motzer (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 378
R. Motzer, Thomas Hutson, H. Glen, D. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, P. Maroto, B. Mellado, B. Melichar, J. Tomasek, H. Kim, K. Wood, C. Dutcus, J. Larkin (2015)
Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, 33
Thomas Hutson, B. Escudier, E. Esteban, G. Bjarnason, Ho Lim, K. Pittman, P. Senico, A. Niethammer, D. Lu, S. Hariharan, R. Motzer (2014)
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 8
T. Graham, G. Box, N. Tunariu, M. Crespo, T. Spinks, S. Miranda, G. Attard, J. Bono, S. Eccles, F. Davies, S. Robinson (2014)
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.Journal of the National Cancer Institute, 106 4
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Staehler, S. Négrier, C. Chevreau, A. Desai, F. Rolland, T. Demkow, Thomas Hutson, M. Gore, S. Anderson, G. Hofilena, M. Shan, C. Peña, C. Lathia, R. Bukowski (2009)
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 20
E. Ciamporcero, K. Miles, Remi Adelaiye, S. Ramakrishnan, Li Shen, Sheng-Yu Ku, S. Pizzimenti, B. Sennino, G. Barrera, R. Pili (2014)
Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma ModelsMolecular Cancer Therapeutics, 14
D. Spigel, T. Ervin, R. Ramlau, D. Daniel, J. Goldschmidt, G. Blumenschein, M. Krzakowski, G. Robinet, B. Godbert, F. Barlesi, R. Govindan, T. Patel, S. Orlov, M. Wertheim, Wei Yu, J. Zha, R. Yauch, Premal Patel, S. Phan, A. Peterson (2013)
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 32
R. Motzer, B. Escudier, Stéphane Oudard, T. Hutson, Camillo Porta, S. Bracarda, Viktor Grünwald, John Thompson, R. Figlin, N. Hollaender, G. Urbanowitz, William Berg, Andrea Kay, D. Lebwohl, A. Ravaud (2008)
Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial
R. Motzer, Thomas Hutson, D. Cella, J. Reeves, R. Hawkins, Jun Guo, P. Nathan, M. Staehler, P. Souza, J. Merchan, E. Boleti, K. Fife, Jie Jin, Robert Jones, H. Uemura, U. Giorgi, U. Harmenberg, Jinwan Wang, C. Sternberg, K. Deen, L. McCann, M. Hackshaw, R. Crescenzo, L. Pandite, T. Choueiri (2013)
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.The New England journal of medicine, 369 8
F. Yakes, Jason Chen, Jenny Tan, K. Yamaguchi, Yongchang Shi, P. Yu, Fawn Qian, Felix Chu, F. Bentzien, B. Cancilla, Jessica Orf, A. You, A. Laird, S. Engst, Lillian Lee, Justin Lesch, Y. Chou, A. Joly (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 10
(2014)
Phase II randomized trial comparing sequential first-line everolimus and secondline sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
E. Rankin, K. Fuh, Laura Castellini, K. Viswanathan, Elizabeth Finger, Anh Diep, Edward LaGory, Mihalis Kariolis, Andy Chan, D. Lindgren, H. Axelson, Y. Miao, A. Krieg, A. Giaccia (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProceedings of the National Academy of Sciences, 111
T. Eisen, C. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, B. Escudier (2012)
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Journal of the National Cancer Institute, 104 2
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Yoshihiko Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, P. Sharma (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
N. Janzen, Hyung Kim, R. Figlin, A. Belldegrun (2003)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.The Urologic clinics of North America, 30 4
A. Dueck, T. Mendoza, S. Mitchell, B. Reeve, K. Castro, L. Rogak, T. Atkinson, A. Bennett, A. Denicoff, A. O'Mara, Yuelin Li, S. Clauser, Donna Bryant, J. Bearden, T. Gillis, J. Harness, R. Siegel, D. Paul, C. Cleeland, D. Schrag, J. Sloan, A. Abernethy, D. Bruner, L. Minasian, E. Basch (2015)
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).JAMA oncology, 1 8
L. Harshman, T. Choueiri (2013)
Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell CarcinomaThe Cancer Journal, 19
A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, J. Laethem, H. Vlierberghe, J. Trojan, F. Kolligs, A. Weiss, S. Miles, A. Gasbarrini, M. Lencioni, L. Cicalese, M. Sherman, C. Gridelli, P. Buggisch, G. Gerken, R. Schmid, C. Boni, N. Personeni, Z. Hassoun, G. Abbadessa, B. Schwartz, R. Roemeling, M. Lamar, Yinpu Chen, C. Porta (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.The Lancet. Oncology, 14 1
(2012)
GLOBOCAN : kidney cancer estimated incidence and mortality , all ages , both sexes
R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy Kim, I. Chen, P. Bycott, C. Baum, R. Figlin (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.The New England journal of medicine, 356 2
D. Viola, V. Cappagli, R. Elisei (2013)
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.Future oncology, 9 8
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, Eunsik Lee, J. Wagstaff, C. Barrios, P. Salman, O. Gladkov, A. Kavina, J. Zarbá, Mei Chen, L. McCann, L. Pandite, D. Roychowdhury, R. Hawkins (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 41
R. McKay, N. Kroeger, W. Xie, Jae-Lyun Lee, J. Knox, G. Bjarnason, M. Mackenzie, L. Wood, S. Srinivas, U. Vaishampayan, S. Rha, S. Pal, F. Donskov, S. Tantravahi, B. Rini, D. Heng, T. Choueiri (2014)
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.European urology, 65 3
M. Nickerson, Erich Jaeger, Yangu Shi, J. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, M. Navratilova, N. szeszenia-Dabrowska, D. Mates, A. Mukeria, I. Holcatova, L. Schmidt, J. Toro, S. Karami, R. Hung, G. Gerard, W. Linehan, M. Merino, B. Zbar, P. Boffetta, P. Brennan, N. Rothman, W. Chow, F. Waldman, L. Moore (2008)
Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 14
Lijun Zhou, Xian-de Liu, Mianen Sun, Xuesong Zhang, P. Germán, S. Bai, Z. Ding, N. Tannir, C. Wood, S. Matin, J. Karam, P. Tamboli, K. Sircar, P. Rao, E. Rankin, D. Laird, A. Hoang, C. Walker, A. Giaccia, E. Jonasch (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene, 35
Chuan Shen, W. Kaelin (2013)
The VHL/HIF axis in clear cell renal carcinoma.Seminars in cancer biology, 23 1
R. Motzer, J. Bacik, L. Schwartz, V. Reuter, P. Russo, S. Marion, M. Mazumdar (2004)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 3
N. Kroeger, T. Choueiri, Jae-Lyn Lee, G. Bjarnason, J. Knox, M. Mackenzie, L. Wood, S. Srinivas, Ulka Vaishamayan, S. Rha, S. Pal, T. Yuasa, F. Donskov, N. Agarwal, M. Tan, A. Bamias, C. Kollmannsberger, S. North, B. Rini, D. Heng (2014)
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.European urology, 65 6
D. Pinato, S. Chowdhury, J. Stebbing (2016)
TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibitionOncogene, 35
T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini, F. Donskov, H. Hammers, Thomas Hutson, Jae-Lyun Lee, K. Peltola, B. Roth, G. Bjarnason, L. Geczi, B. Keam, P. Maroto, D. Heng, M. Schmidinger, P. Kantoff, A. Borgman-Hagey, C. Hessel, C. Scheffold, G. Schwab, N. Tannir, R. Motzer (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
B. Sennino, T. Ishiguro-Oonuma, Ying‐Ying Wei, R. Naylor, C. Williamson, Vikash Bhagwandin, S. Tabruyn, W. You, H. Chapman, J. Christensen, D. Aftab, D. McDonald (2012)
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.Cancer discovery, 2 3
R. Motzer, E. Jonasch, N. Agarwal, C. Beard, S. Bhayani, G. Bolger, Sam Chang, T. Choueiri, B. Costello, I. Derweesh, Shilpa Gupta, S. Hancock, Jenny Kim, T. Kuzel, E. Lam, C. Lau, E. Levine, D. Lin, M. Michaelson, T. Olencki, R. Pili, E. Plimack, E. Rampersaud, B. Redman, C. Ryan, J. Sheinfeld, B. Shuch, K. Sircar, B. Somer, R. Wilder, M. Dwyer, Rashmi Kumar (2015)
Kidney cancer, version 3.2015.Journal of the National Comprehensive Cancer Network : JNCCN, 13 2
J. Ko, W. Xie, N. Kroeger, Jae-Lyun Lee, B. Rini, J. Knox, G. Bjarnason, S. Srinivas, S. Pal, T. Yuasa, M. Smoragiewicz, F. Donskov, R. Kanesvaran, L. Wood, D. Ernst, N. Agarwal, U. Vaishampayan, S. Rha, T. Choueiri, D. Heng (2015)
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.The Lancet. Oncology, 16 3
K. Gupta, Jeffrey Miller, Jim Li, M. Russell, C. Charbonneau (2008)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.Cancer treatment reviews, 34 3
B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J. Bay, I. Bodrogi, A. Jagiełło-Gruszfeld, N. Moore (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 370
T. Powles, M. Staehler, B. Ljungberg, K. Bensalah, S. Canfield, S. Dabestani, R. Giles, F. Hofmann, M. Hora, M. Kuczyk, T. Lam, L. Marconi, A. Merseburger, A. Volpe, A. Bex (2016)
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.European urology, 69 1
B. Leibovich, M. Blute, J. Cheville, C. Lohse, I. Frank, E. Kwon, A. Weaver, A. Parker, H. Zincke (2003)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 97
A. Gustafsson, Danuta Martuszewska, M. Johansson, C. Ekman, S. Hafizi, B. Ljungberg, B. Dahlbäck (2009)
Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and SurvivalClinical Cancer Research, 15
W. Gradishar, Benjamin Anderson, Ron Balassanian, Sarah Blair, H. Burstein, Amy Cyr, Anthony Elias, William Farrar, Andres Forero, Sharon Giordano, Matthew Goetz, Lori Goldstein, S. Isakoff, Janice Lyons, P. Marcom, I. Mayer, B. McCormick, Meena Moran, Ruth O'Regan, Sameer Patel, Lori Pierce, Elizabeth Reed, K. Salerno, L. Schwartzberg, Amy Sitapati, Karen Smith, Mary Smith, H. Soliman, G. Somlo, M. Telli, John Ward, Dorothy Shead, Rashmi Kumar (2017)
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.Journal of the National Comprehensive Cancer Network : JNCCN, 15 4
F. Shojaei, Joseph Lee, Brett Simmons, A. Wong, Carlos Esparza, Pamela Plumlee, Junli Feng, A. Stewart, D. Hu-Lowe, J. Christensen (2010)
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.Cancer research, 70 24
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, C. Porta, S. Bracarda, V. Grünwald, John Thompson, R. Figlin, N. Hollaender, A. Kay, A. Ravaud (2010)
Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 116
G. Gibney, S. Aziz, R. Camp, P. Conrad, Brian Schwartz, C. Chen, W. Kelly, Harriet Kluger (2013)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 24 2
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, F. Group (2008)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 372
R. Motzer, Thomas Hutson, H. Glen, M. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, J. Maroto, B. Mellado, B. Melichar, J. Tomasek, A. Kremer, H. Kim, K. Wood, C. Dutcus, J. Larkin (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.The Lancet. Oncology, 16 15
B. Ljungberg, K. Bensalah, S. Canfield, S. Dabestani, F. Hofmann, M. Hora, M. Kuczyk, T. Lam, L. Marconi, A. Merseburger, P. Mulders, T. Powles, M. Staehler, A. Volpe, A. Bex (2010)
EAU guidelines on renal cell carcinoma: 2014 update.European urology, 67 5
T. Choueiri, S. Pal, D. McDermott, D. McDermott, S. Morrissey, K. Ferguson, J. Holland, W. Kaelin, J. Dutcher (2014)
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
Parminder Singh, N. Agarwal, S. Pal (2015)
Sequencing Systemic Therapies for Metastatic Kidney CancerCurrent Treatment Options in Oncology, 16
The Lancet Oncology – Unpaywall
Published: Jul 1, 2016
Access the full text.
Sign up today, get DeepDyve free for 14 days.